2005 sales: +18% (+15% organic). 2005 4th quarter sales: +14% (+10% organic)

(1)Germany, Belgium, Italy, Spain and Portugal.
(2) Other countries

Group continued to post dynamic growth in the 4 th quarter in France and at its subsidiaries. With 18% growth for the year, the sales have doubled over the last five years.

• France  (+20%): the progression essentially results form new treatments by sublingual delivery, while also benefiting from an expanded offer of services.
• Subsidiaries (+23%, organic +15%): Growth was particularly sustained in Germany (+27%), thanks to new treatments by sublingual delivery and the end of regulatory discount, with the other subsidiaries enjoying 7% organic growth. In Spain and Portugal , the integration of IPI went well, enabling the Group to nearly double its market share.
• Distributors (-2%): the pursuit of the expansion in the Europe region was not enough to offset lower sales in North Africa and the Middle East in relation to an exceptional 2004.

The Group confirms its forecast of a 5th consecutive year of growth in profitability. 2005 was very satisfactory in terms of both business activity and the confirmation of the option of development of allergen tablets by sublingual route.